Skip to main content
Pulike Biological Engineering,Inc. logo

Pulike Biological Engineering,Inc. — Investor Relations & Filings

Ticker · 603566 ISIN · CNE1000025N0 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,080 across all filing types
Latest filing 2017-04-16 Governance Information
Country CN China
Listing Shanghai Stock Exchange 603566

About Pulike Biological Engineering,Inc.

http://en.pulike.com.cn/

Pulike Biological Engineering, Inc. specializes in the research, development, and production of veterinary biological products and pharmaceutical preparations. The company focuses on animal disease prevention through the manufacture of high-end vaccines, diagnostic reagents, and veterinary medicines. Its product range primarily serves the swine and poultry sectors, featuring advanced biologicals such as genetically engineered vaccines and synthetic peptide products. Pulike maintains a strong emphasis on technological innovation, utilizing national-level research platforms to develop solutions for complex animal health challenges. The company’s core activities encompass the entire value chain from basic biotechnology research to the commercialization of veterinary health solutions, aiming to improve livestock productivity and biosecurity.

Recent filings

Filing Released Lang Actions
关于修订公司章程的公告
Governance Information Classification · 95% confidence The document is a company announcement regarding amendments to the company's articles of association (company bylaws). It details specific changes to the company's registered address, business scope, and senior management structure. There is no financial data, no mention of annual or interim reports, no voting results, no executive compensation details, and no regulatory certifications. The document is a formal announcement of governance-related changes, specifically to the company's internal rules and structure. Therefore, it fits best under Governance Information (CGR). The document length is short and it is not an announcement of a report publication, so it is not RPA. Hence, the classification is CGR with high confidence.
2017-04-16 Chinese
第二届董事会第二十三次会议决议公告
Board/Management Information Classification · 95% confidence The document is a detailed announcement of the resolutions passed at the 23rd meeting of the second board of directors of 普莱柯生物工程股份有限公司, held on April 14, 2017. It includes voting results on various agenda items such as approval of the 2016 annual report, board work report, general manager's report, independent directors' report, audit committee report, internal control reports, financial statements, profit distribution plan, appointment of accounting firm, adjustments to fundraising projects, and nomination of candidates for the third board of directors. It also contains personal resumes of the nominated directors and senior management. The document is a formal board meeting resolution announcement, focusing on board decisions and management nominations, rather than the full annual report or financial statements themselves. It is not a call transcript, earnings release, or regulatory filing of a different nature. Therefore, the best fitting category is Board/Management Information (MANG), as it announces changes and decisions related to the company's board and senior management.
2017-04-16 Chinese
募集资金年度存放与使用情况鉴证报告
Regulatory Filings
2017-04-16 Chinese
独立董事2016年度述职报告
Management Reports Classification · 95% confidence The document is titled as an "Independent Director 2016 Annual Report" for a company, detailing the independent directors' profiles, their attendance at board and shareholder meetings, opinions on various company matters, and their oversight activities during the year 2016. It includes detailed descriptions of their duties, evaluations of company governance, internal controls, and other compliance matters. The content is a comprehensive report on the independent directors' annual work and observations, which aligns with a Management Reports (MDA) filing type, as it provides management's detailed explanation of company governance, business trends, and oversight activities rather than a full annual financial report or a simple announcement. The document length is under 5,000 characters but contains substantive content, not just an announcement or certification, so it is not an RPA or RNS. Therefore, the best fit is Management Reports (MDA).
2017-04-16 Chinese
关于对暂时闲置募集资金和自有资金进行现金管理的实施公告
Capital/Financing Update Classification · 95% confidence The document is an announcement by 普莱柯生物工程股份有限公司 regarding the implementation of cash management of temporarily idle raised funds and own funds. It details the purchase of various low-risk financial products, including amounts, expected returns, and risk control measures. The document is a formal public disclosure about the company's use of idle funds for cash management, including specifics of financial products purchased and risk controls. It does not contain comprehensive financial statements or detailed financial performance data typical of an Annual Report or Interim Report. It is not a report publication announcement since it contains substantive information about the cash management activities. The document fits best into the category of Capital/Financing Update (CAP), as it updates on the company's financing activities related to cash management of idle funds and investments in financial products. The document length is 4059 characters, which is sufficient for a detailed announcement but not a full financial report. Therefore, the classification is CAP with high confidence.
2017-04-16 Chinese
关于根据财政部规定调整“营业税金及附加”科目的公告
Regulatory Filings Classification · 95% confidence The document is a company announcement regarding an accounting policy change related to tax accounting, specifically adjusting the classification of certain tax expenses in the financial statements. It references a Ministry of Finance regulation and details the impact on financial statement line items. The document is short (1154 characters) and does not contain full financial statements or comprehensive financial data. It is an announcement of an accounting policy change rather than a full audit report or annual/interim report. It does not fit into categories like Annual Report, Interim Report, or Audit Report. It is a regulatory announcement about accounting policy adjustment, which fits best under Regulatory Filings (RNS).
2017-04-16 Chinese

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.